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Abstract
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Rexinoids are powerful ligands that bind to retinoid-X-receptors (RXRs) and show great promise
as therapeutics for a wide range of diseases, including cancer. However, only one rexinoid,
bexarotene (Targretin TM) has been successfully transitioned from the bench to the clinic and used
to treat cutaneous T-cell lymphoma (CTCL). Our goal is to develop novel potent rexinoids with a
less untoward side effect profile than bexarotene. To this end, we have synthesized a wide array of
rexinoids with EC50 values and biological activity similar to bexarotene. In order to determine
their suitability for additional downstream analysis, and to identify potential candidate analogs for
clinical translation, we treated human CTCL cells in culture and employed microarray technology
to assess gene expression profiles. We analyzed twelve rexinoids and found they could be stratified
into three distinct categories based on their gene expression: similar to bexarotene, moderately
different from bexarotene, and substantially different from bexarotene. Surprisingly, small changes
in the structure of the bexarotene parent compound led to marked differences in gene expression
profiles. Furthermore, specific analogs diverged markedly from our hypothesis in expression of
genes expected to be important for therapeutic promise. However, promoter analysis of genes
whose expression was analyzed indicates general regulatory trends along structural frameworks.
Our results suggest that certain structural motifs, particularly the basic frameworks found in
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analog 4 and analog 9, represent important starting points to exploit in generating additional
rexinoids for future study and therapeutic applications.

Graphical Abstract

Author Manuscript

Keywords
Rexinoids; RXR; Gene Expression; Microarrays; Analytics; Cancer

Introduction
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Bexarotene is a synthetic pan-agonist for all known isoforms (α, β, γ) of the retinoid X
receptor (RXR)—a transcriptional factor that often partners with other nuclear receptor
(NR)1 transcription factors to regulate several critical pathways in the body [1]. For
example, a few nuclear receptors for which RXR plays a partnering role include the retinoic
acid receptor (RAR), the vitamin D receptor (VDR), the thyroid hormone receptor (TR), the
liver X receptor (LXR), the constitutive androstane receptor, and the peroxisome proliferator
activated receptor (PPAR). Most often, the NRs promote gene expression when associated
with a specific molecular ligand, a DNA target site, and any necessary partnering receptor.
The specific molecular ligand(s) associates with a NR ligand-binding domain (LBD) in the
receptor that mediates a conformational change inducing dimerization, recruitment of cofactors, and finally binding to a corresponding hormone responsive element (HRE) on the
DNA. It is remarkable that at least one isoform of human RXR is expressed in every tissue
type, and coupled with the fact that RXR impacts so many other pathways, it is
understandable that small structural changes in RXR agonists (rexinoids) might give rise to
highly differential gene expression [2,3].

Author Manuscript

While TR, RAR and VDR were all initially believed to homodimerize prior to association
with their corresponding HREs, they must partner with RXR to form heterodimers instead
[4,5]. An isomer of all trans-retinoic acid (ATRA), 9-cis-retinoic acid (9-cis-RA), is one of
several natural rexinoids that binds to RXR and in most cases drives RXR homodimer

1Abbreviations: 9-cis-RA 9-cis-retinoic acid; ATRA all trans retinoic acid; CTCL cutaneous T cell lymphoma; DS divergence score;
FXR; farnesoid X receptor; HRE hormone-responsive element; LBD ligand-binding domain; LXR liver X receptor; NSCLC nonsmall cell lung cancer; NR nuclear receptor; PCA principal component analysis; PPAR peroxisome proliferator-activated receptor;
RA retinoic acid; RAR retinoic acid receptor; RXR retinoid X receptor; RXRE RXR-responsive element; tPSA topological polar
surface area; TR thyroid hormone receptor; VDR vitamin D receptor
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formation and binding to RXR HREs (RXREs) [6,7]. There are several natural and synthetic
“canonical” rexinoids that bind tightly to RXR’s LBD in addition to “noncanonical”
rexinoids that bind loosely—such as (R)-Etodolac (an NSAID) and rhein (from rhubarb)—
as well as ligands that target alternate surface binding sites on RXR [8]. When partnering
with other NRs, the LBD of RXR may be occupied or vacant. For the RXR-VDR
heterodimer, the RXR LBD has been reported to be vacant [9]. For the RXR-LXR
heterodimer, however, the RXR LBD may be occupied by ligands that in many cases
promote the functioning of the heterodimer [10].

Author Manuscript

From several studies like the above, investigating the occupancy of the RXR LBD in the
active RXR-heterodimer assemblies, two primary classifications of RXR-heterodimers—
permissive and nonpermissive—emerged. For purely nonpermissive RXR heterodimers,
only heteropartner selective ligands will affect transcriptional activity, whereas for
permissive RXR heterodimers both rexinoids and heteropartner ligands can promote activity
[11]. While the RXR-TR, RXR-VDR and RXR-RAR heterodimers are primarily
nonpermissive, where RXR is “silent” in most (but not every) set of conditions for VDR and
TR, the RXR-RAR heterodimer can exhibit enhanced activity when treated with both RAR
selective agonists and certain rexinoids. In fact, certain antagonist rexinoids have been
observed to activate RXR-RAR, and thus the RXR-RAR might reasonably be termed
conditionally permissive [12]. The RXR-LXRs, RXR-PPARs, and RXR-FXRs are fully
permissive.

Author Manuscript

The potential of a rexinoid to stimulate permissive RXR-heterodimer activity, or remove
RXR from participating in nonpermissive heterodimers—thereby blocking those pathways
—has increased the risk associated with rexinoid agonists as clinical therapeutics. For
example, the 9-cis-RA rexinoid and other rexinoid agonists have been reported to inhibit the
activity of nonpermissive RXR-heterodimers with VDR and TR due to rexinoid-driven
formation of competing RXR-RXR homodimers [13–16]. In a similar manner, 1,25dihydroxyvitamin D3 (1,25D) and T3—the agonist ligands specific for VDR and TR,
respectively—have been observed to arrest other pathways where RXR-RXR participates
because these ligands stimulate RXR-VDR and RXR-TR formation, removing the RXR
protein from a limited reservoir [17]. Additionally, certain rexinoids can stimulate
hypertriglyceridemia by activating the permissive RXR-LXR heterodimer. Thus, two
important issues to consider in creating novel rexinoids to explore as clinical therapeutics
include RXR-heterodimer selectivity and potency.

Author Manuscript

Bexarotene is a synthetic rexinoid approved for use by the FDA for the efficacy of its
antineoplastic properties in the treatment of cutaneous T-cell lymphoma (CTCL). Despite a
growing number of reported synthetic rexinoids, only a few have advanced into clinical trials
[18,19]. Bexarotene has also been examined as an off-label treatment for other cancers
including non-small cell lung cancer (NSCLC) and breast cancer. Additionally, there has
been interest in exploring bexarotene and other rexinoids to treat diabetes, Alzheimer’s
disease, Parkinson’s disease, and multiple sclerosis [20–24]. The side effect profile of
bexarotene is a serious concern, and as such the development of more potent RXR agonists
with more limited side-effect profiles, would be of great benefit.
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A more potent rexinoid would enable reduced dosage requirements, possibly mitigating the
severity of the known side-effects. Additionally, it is likely, given the hetero- and homodimer
binding modalities of RXR, as well as the large number of RXR partnering receptors that an
alternative rexinoid may have a wholly different side-effect profile from bexarotene, which
could serve to mitigate the side-effect concerns associated with use of this kind of drug.

Author Manuscript

The goal of the present study is to explore the viability of several synthetic bexarotene
analogs (Fig 1). Specifically, we probed how our suite of analogs might influence the
potency of the desirable and undesirable effects of this drug. To this end, eight rexinoids
developed by our group (analogs 1–3, 5, 8, and 10–12) and five previously reported
rexinoids (bexarotene and analogs 4, 6, 7, and 9) were used to dose a human cell culture
cutaneous T-cell lymphoma cell line (HuT78) to determine promising candidate analogs for
further experimentation. Human CTCL cells were treated in culture with an analog or
bexarotene and studied using gene expression analysis.
Analysis of the findings is directed towards cancer-related gene activity, with the goals of
both eliminating analogs which behave unpredictably, as well as deciphering which analogs
stand apart as the most promising for future experimentation. Rexinoid-mediated gene
regulation in HuT78 cells is examined in light of including (1) the hypothesized apoptotic
mechanism of the RXR/PPARγ dimer, which is likely the primary source of the
antineoplastic activity of rexinoids, (2) potential cell cycle arresting effects, (3) influence on
the thyroid hormone axis, (4) dyslipidemic effects, and (5) possible metabolic effects
associated with the citric acid cycle.

Author Manuscript

Our results reveal that the studied analogs sort into 3 distinct groupings, separated by both
the number and magnitude of their differences from bexarotene. We analyze these novel
molecules by group as well as by promoter composition, and present five analogs which we
propose as promising candidates for future study.

Experimental
Compound analysis and instrumentation

Author Manuscript

All 1H NMR spectra were acquired at 400 MHz or 500 MHz on Bruker or Varian
spectrometers. Chemical shifts (δ) are listed in ppm against the non-deuterated solvent peaks
as an internal reference. Coupling constants (J) are reported in Hz, and the abbreviations for
splitting include: s, single; d, doublet; t, triplet; q, quartet; p, pentet; m, multiplet; br, broad.
All 13C NMR spectra were acquired on Bruker instruments at 125.8 MHz or 100.6 MHz.
Chemical shifts (δ) are listed in ppm against solvent carbon peaks as an internal reference.
High resolution mass spectra were recorded using either a JEOL GCmate(2004), a JEOL
LCmate(2002) high resolution mass spectrometer or an ABI Mariner (1999) ESI-TOF mass
spectrometer. Melting points were assayed on a Thomas Hoover capillary melting point
apparatus. All tested compounds were analyzed for purity by combustion analysis through
Columbia Analytical Services (formerly Desert Analytics in Tucson, AZ), except for analog
4 which was purchased from TOCRIS Biosciences and labelled to be ≥ 97% by HPLC
according to the company’s specifications. The spectroscopic and characterization data for
each compound is provided as well as their 1H-NMR and 13C-NMR spectra. Individual
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compound spectra and further details relating to compound analysis may be found in the
Appendix.
HuT78 treatment and mRNA harvesting

Author Manuscript

Human CTCL cells (HuT78) cultured in Roswell Park Memorial Institute (RPMI) Medium
#1640 + 10% charcoal stripped Fetal Bovine Serum (FBS) + Sodium Pyruvate (NaPyr) +
Penicillin/Streptomycin (P/S) were treated with bexarotene or bexarotene analog. After a 24hour treatment period with either bexarotene or the indicated analog at 100nM, cells were
transferred along with media into 15 ml conical tubes and centrifuged for 5 minutes at 300g
whereupon 1 mL phosphate-buffered saline (PBS) was added to each and the contents were
then aspirated, and 1mL of cold PBS was added to each group. The cells were then
progressively vortexed and centrifuged and ultimately treated with Aurum Total RNA Lysis
solution (Bio-Rad, Hercules, CA). The RNA yield was quantified via UV spectrophotometry
and the RNA quality was estimated using the A260/A280 and A260/A230 ratios. RNA
concentrations from each treatment were in the range of 0.40 μg/μl to 0.80 μg/μl, with an
average concentration of 0.60 μg/μl.
cDNA generation

Author Manuscript

RNA from cells treated with Bexarotene and from cells treated with a single analog from
above treatments was thawed as a pair and hybridized with 1 μl of reverse transcriptase (RT)
primer each (1x Cy3 green and 1x Cy5 red). The tubes containing each treatment were
brought to concentration parity using nuclease-free water such that both final 11 μl volumes
contained an RNA concentration of 0.2 μg/μl. The tubes were heated, subsequently placed
on ice, and then added to a reaction mix composed of Invitrogen SuperScript II first-strand
buffer (Invitrogen, Carlsbad, CA), more nuclease-free water, dNTP mix, an RNase inhibitor,
and RT enzyme utilizing the Array 350 kit (Genisphere, Hatfield, PA).
The combined contents were incubated and then had their reactions halted with the addition
of solution containing 0.5 M sodium hydroxide (NaOH) and 50 mM ethylenediaminetetraacetic acid (EDTA). The tube contents were then again incubated and the
reaction was neutralized with 1 M Tris-HCl to a pH of 7.5. The neutralized solutions were
combined and a Qiagen PCR cleanup kit (Qiagen, Germantown, MD) was employed to
isolate the cDNA portion. Vacufugation was performed to bring the PCR cleanup results to a
usable volume. The resultant 10 μl volume of concentrated cDNA was combined with 2 μl of
locked nucleic acid (LNA) dT blocker, 17 μl of nuclease-free water, and 29 μl of a 2X
formamide-based hybridization buffer.

Author Manuscript

Microarray preparation, hybridization, and analysis
Human MI ReadyArrays were procured from Microarrays Inc. (Huntsville, AL). Each array
consists of 48,958 individual wells conforming to the Human Exonic Evidence Based
Oligonucleotide (HEEBO) standard. Before applying cDNA solutions, each slide was
treated with a prehybridization/blocking procedure. This procedure was accomplished using
a bovine serum albumen (BSA) ssDNA solution to reduce non-specific binding events.
Slides were incubated and washed by gentle rocking in vials with 3 M NaCl/0.3 M sodium
citrate (20xSSC), 10% sodium dodecyl sulfate (SDS), and the BSA solution. Each slide was
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then transferred to a series of separate vials and washed five times by gentle agitation in
millipore water. Rinsed and dried slides had the cDNA solution applied to them while
warmed. Each was covered, stored in an individual humidified hybridization chamber, and
placed in a hybridization oven with gentle agitation.

Author Manuscript

After incubation, the slides were agitated in a shaker with a series of progressively less
concentrated treatments of SSC and SDS. After their final wash, slides were dried and
treated for visualization with a solution composed of nuclease-free water, 2X formamidebased hybridization buffer, Cy3 and Cy5 3DNA capture reagents. Slides were then once
again incubated in a humidified hybridization chamber. Post-DNA hybridization washes
were performed similar to pre-hybridization washes, and then the chips were dried and
immediately moved to be scanned by a GenePix 4000B microarray scanner using the
Genepix Pro® 7 Microarray Acquisition and Analysis software. Each slide was checked for
abnormalities and backgrounding effects and then log-transformed luminosity results were
exported to Microsoft Excel.
Gene expression analysis, grouping
Gene expression analysis was performed along several lines of investigation. The expression
profile of each analog was culled to a list of only cancer-related study genes for the present
investigation (Appendix) and then the analogs were compared to each other using this data
sub-set (raw data in [25] ). The trends in these profiles were recorded and the analogs were
split into three groupings based upon the magnitude and enumeration of their differences
from their parent molecule.

Author Manuscript
Author Manuscript

Gene expression was analyzed as absolute fold changes as compared to bexarotene using
expression data for the genes outlined in the Appendix, with the dataset described in [25].
The number of genes from the Appendix that fell into three categories were determined. The
cutoffs thresholds for these categories are expression levels of |1.2|, |1.8|, and |2.4| foldchange differences from bexarotene (absolute value indicates that fold-changes could be in
either direction, thus only magnitude was considered). Each analog was grouped by
comparing these changes. Group one contains analogs that elicited the most changes in
expression: four or more genes from the study group demonstrating greater than a |1.8|-fold
difference from bexarotene. Group two contains analogs for which measured fold changes
had lower magnitudes than group one: one or more genes from the study group revealed
greater than a |1.8|-fold difference from the parent molecule, and/or five or more total
measured differences of |1.2|-fold magnitude or greater. Group three demonstrates the
expression most similar to bexarotene: zero to four measured differences of less than |1.8|fold from bexarotene.
Gene expression analysis, heat maps
The expression profile of each analog was further analyzed using heat maps generated with
web-enabled heat mapping software provided by Wishart Research Group through their
service at www.heatmapper.ca [26]. Images were generated using single linkage
methodology and Euclidian distance measuring.
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Principal Component Analysis was performed on the data from Table 1 following a
methodology prescribed in literature [27]. Bexarotene was kept as its own separate group
and the other compounds were grouped according to similarities in the magnitudes of their
expression. The ellipses represent the 95% confidence interval.
Gene expression analysis, divergence scoring

Author Manuscript

To further differentiate the analogs from each other, the expression elicited after analog
treatment was compared using another metric referred to herein as divergence scoring (DS),
a novel intraexperimental decision tool. Several well-characterized genes were selected as a
subset of the study group [25] using two criteria, their impact in differentiating the analogs
from each other, and the importance of directionality of regulation as understood by the
present literature. Divergence in this case means the extent to which the gene expression of
each individual gene elicited by the analog was performing contrary to the presumed
direction of expression of that gene based on its ontology. For example, we hypothesized
that better analogs would increase the apoptotic potential of the treated CTCL cells, and a
departure from this expression hypothesis results in a divergence.

Author Manuscript

For every DS gene on each analog, fold-change differences from the parent molecule were
either discarded or aggregated depending on whether the recorded value matched a
predictive model ([25]. The predictive model operates on a fundamental design presumption
that the child molecule should be an improved version of the parent molecule. To this end, in
those instances where the recorded data value did align with the predicted value from the
model, the observed difference between the child and parent was discarded [25]. For the
instances in which there was a mismatch between the directional expression difference of the
analog and bexarotene, and that mismatch did not align with the predictive model, the
absolute value of the observed data point was recorded and then aggregated. The aggregate
value of recorded mismatches was averaged across the total number of DS genes, and the DS
for the given analog was recorded as this value.
Docking analysis
Docking of ligands to the RXR binding domain has been reviewed and was performed in
this study with AutoDock 4.2 [28,29]. Ligands were prepared and energy minimized with
Avogadro [30]. Coordinates for the protein were taken from the protein data bank structure
1MVC [31], and Arg316 and Ile268 were treated as flexible. Docking was performed with
the Lamarckian genetic algorithm using 25 million energy evaluations per dock. A total of
250 docks were performed per compound. Poses were visualized with Chimera [32].

Author Manuscript

Analysis of putative RXR binding motifs
Names of cancer-related study genes were converted to National Center for Biotechnology
Information (NCBI) Reference Sequence Database ID numbers (RefSeq ID) using the ID
conversion tool available from DAVID (Database for Annotation, Visualization and
Integrated Discovery; [33,34]). Of the study genes, 92 were successfully converted to
RefSeq IDs for compatibility with the Pscan software tool. Presumptive promoter regions for
all 92 genes were scanned for the presence of nine RXR binding motifs using Pscan [35].
Steroids. Author manuscript; available in PMC 2019 July 01.
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Scanned regions were limited to −450 to +50 base pairs (bp) with respect to the transcription
start site. This study focused on identifying enriched RXR motifs using 9 well-defined
Position Frequency Matrices (PFMs) from the JASPAR 2016 database. The 9 RXR binding
motifs along with their corresponding JASPAR 2016 Matrix ID numbers are as follows:
PPARγ::RXRα (MA0065.1), PPARγ::RXRα_v2 (MA0065.2), RXRα::VDR (MA0074.1),
NR1H2::RXRα (MA0115.1), RARα::RXRα (MA0159.1), NR1H3::RXRα (MA0494.1),
RXRα (MA0512.2), RXRβ (MA0855.1), and RXRγ (MA0856.1). Genes were determined
to contain the motif if the computationally-determined matching score was higher than
expected when compared to the whole genome promoter set. Consensus sequences for each
gene containing the relevant RXR motif were converted to graphical Sequence Logos using
the web-based application WebLogo [36,37].
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Genes were scored manually based on the presence (1) or absence (0) of each of the 9 RXR
motifs. A heat map of RXR motifs per gene was generated using ClustVis and hierarchical
cluster analysis based on Euclidian correlation distances and complete linkage methods [27].
Unit variance scaling was applied to each row. Promoter regions for each gene cluster were
again analyzed using Pscan to determine which RXR binding motifs were significantly
(p≤0.05) enriched in each cluster. Average gene expression per cluster was determined for
each of the 12 analogs using Excel. For each analog, two-sample t-tests were used to
determine whether average gene expression for each cluster differed significantly from the
remaining study genes.

Results
Gene expression analysis

Author Manuscript

In order to develop a more powerful structure-activity framework (SAR) framework by
which to synthesize novel rexinoids, we sought to analyze gene expression of an array of
published rexinoids. We wanted to determine which molecules maximized gene expression
of pathways advantageous for rexinoid treatment of cancer cells. When treated with
bexarotene analogs, HuT-78 cell cultures (derived from human cutaneous T cell lymphoma
cells) produced substantially different mRNA expression profiles when compared to those
produced by bexarotene (Figs 2, 3a, 3b, and 3c). Our investigation is focused on differential
mRNA production as it relates to the treatment outcomes of patients primarily with CTCL,
but also NSCLC and breast cancer. We therefore present results germane to the treatment of
these three cancers. Of the 12 analogs studied, each produced an mRNA profile which fits
into one of 3 general categories.

Author Manuscript

The first of these categories, “Group 1,” includes analogs 2, 4, and 5 (Fig 3a). This group
shows a trend of similar behavior to bexarotene for the genes in the study group, but each
compound has more than a few instances of stark product differences from the parent
molecule. Categorically, analogs which fit in to this group have 4 or more genes from the
study group gene list (Appendix) which demonstrate greater than a 1.8-fold difference in
gene expression from bexarotene.
Group 2 members (analogs 1, 6, 10, and 11 seen in Fig 3b) lack the distinctive drastic
differences from bexarotene compared to the Group 1 analogs yet contains species which
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produce mRNA profiles that are similar to bexarotene and tend to differ only in that they are
either slightly more or less active for particular study genes. Categorically, this group
consists of analogs for which either: less than 4 genes from the study group show a greater
than 1.8-fold difference from bexarotene, in either direction, and/or analogs which have 5 or
more total measured differences from bexarotene for the gene study group of greater than a
1.2-fold difference in either direction. Unlike group 1, this second group has a milder folddifference in gene-specific mRNA production when compared to bexarotene. For the
overwhelming majority of the genes of interest, group 2 members’ gene products are within
a 1-fold change as compared to their parent molecule (>75% of study genes within a +/
− 0.5-fold change). Group 2 members trend towards being only slightly more or slightly less
active than bexarotene with respect to the study genes.
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Group 3 analogs (3, 7, 8, 9, and 12 seen in Fig 3c) consists of compounds which have 4 or
fewer total measured differences from bexarotene at the 1.2-fold level, and further did not
contain any members which demonstrated for any study gene greater than a 1.8-fold
difference from bexarotene (a constraint which would categorize an analog as a member of
group 2).
Outliers and divergence scoring

Author Manuscript

In order to further differentiate rexinoid characteristics and attractiveness as potential
therapeutics, we developed a metric to probe undesirable gene expression, the Divergence
Score. This evaluation probes gene expression by each molecule to determine how the
expression deviates from expected results. Divergence scores (DS) were assigned to each
analog to facilitate comparison to group cohorts on a relative measurement of gene-specific
performance predictability. These results are mapped in Fig 4 and a heat map analysis of DS
genes is shown in Fig 5. Genes for this scoring method were selected as a subset of the
study’s gene list for their well-understood features in current literature and the certainty with
which the effects of the directionality of their regulation is understood (Appendix and [25]).
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For group 1, Analog 5 has the most total substantially different gene regulation (Fig 3a),
with 8 differentially regulated mRNAs (total measured differences = 10, total measured
differences over the 1.8-fold level = 8). Analog 2 has the fewest total substantially different
gene regulation (Fig 3a), with 5 differentially regulated mRNAs (total measured differences
= 9, total measured differences over the 1.8-fold level = 5), and analog 2 has the highest DS
for this group, and the second highest overall DS at 0.32 (analog 4 = 0.19, 5 = 0.13), making
it a less attractive study candidate compared to its peers (Fig 4). Analog 5 appears to be the
most attractive candidate from Group 1, with both substantially high differences from
bexarotene in terms of differential gene product abundance, as well as its comparatively low
divergance scoring versus its group peers (DS = 0.13), indicating that, compared to its group
members, biological activity of analog 5 is more in line with what we might expect from an
anti-oncogenic molecule (Figs 3a and 4).
Among group 2 analogs, analog 6 has the most total measured differences from bexarotene
with 12 (Fig 3b). Both it and analog 1 are the only two members of this group to have
measurements from the gene study group of greater than a 1.8-fold change from bexarotene.
Analogs 11 and 10 are tied for the fewest measured differences, with 5, while analog 1 has
Steroids. Author manuscript; available in PMC 2019 July 01.
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the highest DS for this group, and highest overall DS at 0.33, making it a less attractive
candidate as compared to its peers (Fig 4) (analog 6 = 0.26, 10 = 0.21, and 11 = 0.29). The
low divergence score of analog 10 in this category (DS=0.21) indicates that, compared to its
group cohorts, it is the most promising member of this group to be an improvement to the
parent molecule (Fig 4).
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Within group 3, analog 3 has the most total measured differences from bexarotene with 2,
while analogs 8, 9, and 12 are tied for the fewest measured differences with 0 (Fig 3c).
Analog 3 has the lowest DS for this group at 0.0499, making it an attractive candidate
compared to its peers (Fig 4). No members of this group have any observed differences from
the gene study group exceeding a 1.8-fold difference from bexarotene. Both analog 3 and
analog 9 have low divergence scores (DS = 0.05, DS = 0.10). For the group of study genes
covered by this investigation, these two appear to produce an mRNA expression profile that
is most likely to be an improvement to the parent molecule, bexarotene (Figs 3c and 4).
Chemical properties of molecules
We sought to determine if the expression groups could in part be described by the physical
nature of the rexinoid molecules (Table 1), covering the solubility of the molecule (cLogP
and cLogS), the topological polar surface area (tPSA, a metric often used to approximate
permeability characteristics), and molecular weight. Taking into account the characteristics
described in Table 1, in general Group 3 analogs tend to have high cLogP, analogs with
lower DS generally correlate with high cLogS as well as a higher MW, and Group 2 analogs
associate with a higher tPSA. Interestingly, Group 1 analogs, which have the most
differential expression from Bexarotene also have the most dissimilar MW from bexarotene
and they also cluster the most tightly on the PCA analysis (see below).

Author Manuscript
Author Manuscript

In order to determine if the characteristics in Table 1 are contributing to the clustering of the
compounds into groups, we undertook Principal Component Analysis (PCA) of the data in
Table 1. PCA is a method to find patterns in the data based upon their correlations. The PCA
analysis is seen in Fig 6 and was analyzed using the expression grouping method described
earlier. The first correlation or principal component in this analysis accounts for over half of
the variation of the sample (PC1 is 52.1%), and the second PC accounts for 34.7% of the
data, together accounting for 84.8% of the variability. Fig 6 demonstrates that generally the
groupings can be explained by the physicality of the compounds (Table 1). Although
compound 11 by this analysis may be closer to Group 1 and compound 10 falls within
Group 3’s characteristics, in general the compounds are clustering by this analysis in the
Groups defined previously by gene expression. Analogs which show the greatest differences
from bexarotene at the level of gene expression (those in Group 1) tend to associate with
each other closely at the level of their physical properties, as seen in the red ellipse (Fig 6).
Group 2 has the most diffuse characteristics (Table 1 and blue ellipse) and this can confound
PCA analysis. However, the characteristics are well correlated to the gene expression
analysis and will serve as a starting point for future studies.
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Because RXR is a promiscuous nuclear receptor, we sought to determine if there was a
difference between the RXR homodimers and/or heterodimers that might mediate the
response elicited by each analog. To accomplish this, we examined a 500 base pair (bp)
presumptive promoter region located at −450 bp through +50 bp relative to the transcription
start site for each of the cancer-related study genes (Appendix). The 500 bp regions were
scanned for the presence of 9 different RXR homo- and heterodimer binding motifs as
defined using 9 well-defined Position Frequency Matrices (PFMs) from the JASPAR 2016
database (Table 2) [38,39]. Approximately 90% of the genes analyzed contained at least one
putative RXR motif (Table 2 and [25]).

Author Manuscript

Study genes were clustered based on the absence or presence of each of the 9 binding motifs
resulting in 11 distinct gene clusters (Fig 7 and [25]). Each cluster was examined to
determine whether their promoters were significantly enriched in any of the RXR motifs
(p<0.05, Table 3). Notably, the RXRα::VDR motif was the most frequently observed motif
and was significantly enriched in 36% (4/11) of the gene clusters (Table 3). In contrast, the
RARα::RXRα motif was only detected in gene promoters associated with cluster 9. Cluster
10 was the only cluster that did not contain any significantly enriched RXR binding motifs
(Table 3).

Author Manuscript

Average gene expression was determined for each cluster and two-sample t-tests were used
to determine whether any of the clusters responded to the 12 bexarotene analogs
significantly differently (p≤0.05) than the remaining cancer-related study genes (Table 4,
[25]). Approximately 73% (8/11) of the gene clusters demonstrated a significant response
following treatment with at least one of the 12 analogs. Of note, analogs 7, 9, 10 and 11 did
not induce a significant response in any of the gene clusters (Table 4).
In order to determine whether there was a difference in the types of RXR motifs that mediate
the response to each analog, we identified motifs that were shared between gene clusters
demonstrating a significant response to rexinoid treatment (Tables 3–5). The RXR::VDR
motif was associated with a significant response to analogs 1–4, 6, and 12, although the
direction of the response (e.g. increased vs. decreased gene expression relative to bexarotene
treatment) varied between the different clusters. Additional RXR heterodimer binding motifs
were identified as possibly mediating the response to analogs 2–6 and 8.

Discussion
Author Manuscript

In the present study, we provide evidence that a family of twelve bexarotene analogs sort
into three categories based upon the frequency and magnitude of differential gene expression
when compared to bexarotene in a CTCL HuT78 human cell culture. Three of the analogs
are previously studied and nine are novel molecules (Fig 1) [40–45]. Within the three
identified categories each analog presents a differing degree of promise for use as a
therapeutic agent. Utilizing these groupings as well as divergence scoring, we are able to
identify which analogs show the most promise for future study. The goal of the present
study, and those which may follow, is to discover which bexarotene analogs are the most
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promising candidates as either more efficacious or less harmful RXR agonists in their
application as chemotherapeutic agents.
RXRs are type-II nuclear receptors (NR) [46] that are transcriptionally inactive in the
absence of an agonist (like bexarotene or a bexarotene-like molecule) due to the presence of
corepressor proteins. Bexarotene and to varying degrees, the suite of twelve analogs
employed in this study, are thought to mimic the binding activity of an endogenous ligand by
binding to RXR and facilitating a protein conformation change that results in receptor
activation. The binding activity for type-II NR ligands in the target pocket is thought to
release repressor molecules and activate the complex to stimulate transactivation and induce
mRNA synthesis. Fig 8 shows the location of this binding pocket near helices 2, 4, and 6 on
RXR.

Author Manuscript

Our findings, as well as those of others studying bexarotene and its analogs, demonstrate
these molecules have anti-oncogenic properties [47]. Variations in fit for the on-target
binding of our suite of study molecules likely induce a range of biological protein
conformations for the corepressor-disassociated RXR complex. We hypothesize there is
likely to be a bexarotene analog that may optimize this biological activity in its use against
CTCL in humans. The current understanding of conformational changes induced by ligandbound rexinoids suggests that the ligand-binding domain undergoes significant structural
rearrangement. Changes to the properties of the ligand may cause this rearrangement to
differentially expose residues important to other NR-associated activity, including potential
coactivation by other molecules [48,49]. This effect indicates that small changes to the
properties of a ligand can exert large influences on the behavior of the NR with which it is
associated.

Author Manuscript

The common side effects of bexarotene include acute pancreatitis, hypertriglyceridemia,
hyperlipidemia, central hypothyroidism, and headaches [50–53]. The discovery of a more
potent chemotherapeutic agent or one with less severe side effects may mitigate the harm
consideration when selecting bexarotene-like treatments as cancer treatment options, thereby
increasing the rate of positive outcomes through reductions in dosage requirements or the
prevalence of side effects.

Author Manuscript

To this end, we have produced molecules with promising variations in the chemical
attributes of bexarotene that may alter the biological activity of RXR upon ligand binding.
While it would be challenging to attribute common structural features that characterize the
three different groups of compounds classified in this study, the compound with the lowest
divergence score in group 1—analog 5 (Fig 4)—shares a common framework based on the
analog 4 framework. Compound 5 differs from 4 by a methyl group substitution for the
hydroxyl group of 4.
The low divergence score for analog 5 (Figs 4 and 9, DS = 0.13) provides compelling
justification to further investigate this potent rexinoid, but also motivates the development of
additional analogs based upon this framework. It is also notable that the compound with the
second lowest divergence across all of the analogs, analog 9 (Fig 4), is a compound that has
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been well-documented to possess potent anti-cancer and anti-tumor activity in the literature
[54–60].
Investigation of the label-approved use of bexarotene for CTCL HuT-78 cell lines, both in
the present study and in others, reveals that p53 pathway activated apoptosis appears to be a
fundamental contributor to the anti-oncogenic activity of bexarotene [61]. The gene product
abundance from BAX, survivin, bcl-2, and other genes are significantly altered by the
presence of bexarotene, and to varying degrees several of our analogs show promise in this
regard by comparison.
Grouping and divergence scoring methodologies

Author Manuscript

Analogs were split into three groups based upon differences in the measurements of gene
product abundance via microarray analysis using a suite of study genes (Appendix). Results
reveal that some of the analogs present distinctly sharp differences from the parent molecule,
bexarotene, while other analogs display more mild differences, and still a third group of
compounds do not reveal substantial differences from bexarotene in the magnitude or
direction of gene regulation. The criteria used to designate these three categories is based on
two factors, the enumeration of gene products from the study group which show differences
from bexarotene, and the magnitude of these changes for each of the study genes.

Author Manuscript

Divergence Scoring [25] is useful to identify which are more likely to be suitable candidates
in future hypothesis testing, however further analysis can lend more information as to how
useful each analog may be compared to its group cohorts. To this end, a relative measure of
scoring the predictability of each analog’s performance was designed, wherein each analog
is scored relative to the others in its divergence from predicted gene directional movement
compared to bexarotene. A subset of genes with well-understood mechanisms was used to
construct a pass/fail filter.
Using improved anti-oncogenic activity as a biomarker, genes which performed in a way
predicted to be an improvement to bexarotene were scored as a ‘pass’ and removed from this
filter, whereas gene expression which functioned in a way that is counterproductive (worse
than bexarotene) were aggregated as failures. Sums of the absolute values of deviations were
divided across the total number of sub-set study genes for which anti-oncogenic activity is
well understood, and the analog was assigned the resulting divergence score. In this way,
large deviations from expectation on a gene-by-gene basis weigh more heavily than do small
deviations. This methodology allows for a quantitative and less biased approach to the
identification of RXR analogs which may possess improved therapeutic efficacy.

Author Manuscript

Identifying the study group of genes
We identified 102 study genes of interest to our investigation by way of examination of
current literature, knowledge of cancer biology, and inferences from well-understood
principles of cellular apoptosis, cell-cycle arrest, and other oncogenic cellular activity. Of
these 102, 20 were selected (Appendix) for their power in differentiating the analogs as
potential candidates for further study.
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This sub-group of 20 genes was used for divergence scoring. BAX (BCL-associated
apoptosis regulator) and BIRC-5 (survivin) are two examples of well-understood genes used
in this subgroup. BAX is a participant in p53-mediated apoptosis (Appendix) and as a
member of the BCL2 group of proteins the products of this gene should be analyzed for
apoptosis regulation. Survivin, an inhibitor of apoptosis, is an often-studied anti-apoptotic
gene known for being able to suppress multiple channels of apoptosis activation [62,63].

Author Manuscript

One example of the power and versatility provided by this type of analysis concerns the
ability to identify which compounds modulate gene expression in a beneficial direction and
further to examine how that group of compounds modulate other gene sets in beneficial
directions. Taking survivin as an example, it is reasonable to hypothesize that drug
candidates down-regulating survivin to a greater extent than bexarotene could potentially be
more effective cancer drugs. Current research has identified that the downregulation of
survivin is linked to increase rates of apoptosis, a key trait of tumor shrinking
chemotherapeutic agents [64]. If we were interested in this specific mechanism, we could
evaluate only analogs which outperform bexarotene in this one regard [25]. Divergence
scoring provides a means of grading across each analog for 19 other well-understood genes
like survivin. We can, using this tool, check whether an analog outperforms bexarotene
according to a model of directionality provided by the current literature, and use this
information to better inform decisions about future research.
Analogs may act through RXR homodimerization or heterodimerization

Author Manuscript

Previous research has indicated that small changes in rexinoid structure may lead to highly
differential gene expression [3,65]. Consistent with this view, our results suggest that
analogs 6 and 12 which have very similar structures, differing only in the presence or
absence of a single fluorine, appear to regulate gene expression through activation of
RXRα/VDR dimers (Table 5). However, analog 12 which contains a fluorine seems to
perform better than bexarotene, while analog 6, which lacks the fluorine residue and
regulates gene activity via the same heterodimer complex yet does not perform as well as
bexarotene. Further, we find that structures that are quite different may act through the same
RXR dimer complex. Analogs 1 and 4 are quite different from one another, yet both appear
to act through the RXRα/VDR dimer. The possibility remains that analog 4 decreases gene
expression through recruitment of different cofactors or inhibition of receptor
conformational changes.

Author Manuscript

The RXRα/VDR dimer is thought to be non-permissive and therefore incapable of
generating a response in the absence of 1,25-dihydroxyvitamin D3 (1,25D3)[66]. However,
in the studies presented here, cells were treated only with bexarotene analogs which
indicates that the analogs are regulating receptor dynamics independent of vitamin D
binding. These findings are consistent with previous reports that indicate that the
RXRα/VDR heterodimer may act as a permissive receptor, at least in some cases [67,68].
Conformational changes of the RXRα/VDR dimer induced solely by 9-cis-retinoic acid (9cis-RA) binding are thought to enhance VDR-DBD stability and may facilitate interactions
with co-regulatory proteins such as SRC1-RID [67].
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For some analogs, it is unclear which RXR dimer is the most probable candidate to mediate
analog activity. For example, analogs 2 and 3 which differ only in the presence of one
(analog 2) or two (analog 3) fluorine atoms were both able to significantly induce expression
of cluster 11 genes. However, because 7 of the 9 RXR motifs examined in this study were
significantly enriched in cluster 11, determination of the functional RXR motif is more
challenging and may limit the use of these analogs in cancer treatments. The strong
correlation between RXR binding motifs and the response to specific analogs demonstrates
that both analog structure and the RXR motifs present in the cis-regulatory region of target
genes will likely determine the direction of the response (e.g. enhance or reduce gene
expression) to various rexinoids.
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Most of the cancer-related study genes contain at least one putative RXR binding motif in
the presumptive 500 bp promoter examined in this study [25]. Gene cluster 10 did not
respond to any of the analogs tested and it is notable that cluster 10 was the only one that
was not enriched in any of the 9 RXR motifs, providing further compelling evidence for the
relevance of our in-silico approach. Further, none of the analogs were able to induce a
significant effect on expression of genes in clusters 8 and 9. Cluster 8 genes are enriched
only in the PPARγ::RXRα_v2 motif while only the RARα::RXRα motif was detected in
cluster 9 genes. Together, these data suggest that neither the PPARγ/RXRα dimer nor the
RARα/RXRα dimer are sufficient to mediate the actions of the 11 Rexinoids tested in this
study. This observation is also consistent with our measured RAR “cross-over” binding
studies suggesting that the ability of these analogs to activate the RAR-RXR heterodimer is
low (data not shown).
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Surprisingly, analogs 7, and 9–11 did not induce a significant change in gene expression for
any of the gene clusters compared to bexarotene. There are several possibilities that can
explain this. First, it is possible that the structure of these analogs prevents receptor
activation or interaction with co-activators. It is also possible that these analogs regulate the
expression of genes that were not represented in the cancer-related study genes selected for
analysis in this study. Finally, these analogs may simply be too similar to bexarotene in their
structure and binding to have differential gene expression versus bexarotene.

Author Manuscript

The sorting of the 12 investigational analogs into 3 groups, each containing compounds with
similar expression profiles, and the further differentiation between the members of these
groups using divergence scoring allows us to make some assessments about the likely
viability of each analog for future testing. Selecting an analog with a low divergence score
suggests that the chosen compound is likely not performing task-critical effects less
effectively than the parent molecule. Also important is selecting a diverse representation of
molecules in the way that they have substantial performance differences compared to
bexarotene.
Given that we have a limited basis to appraise an analog regarding exactly how drastic a
difference from bexarotene may be desirable, we assert that it is prudent to not disqualify a
candidate because of this metric. Instead, we select analogs representing the best candidate
from each group, analog 5 from group 1, containing substantial differences from bexarotene
and the best divergence score among its peers—analog 10, the best divergence scoring
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species from group 2 which represents molecules with mild differences from bexarotene—
and lastly analog 3 from group 3.
We are interested in both analogs 3 and 8 together from the third group. These two
compounds have attractive DS compared to all analogs as a whole and further, we are
interested in analog 8 in particular because analog 8 also shows promise from other research,
and its DS compared to all other analogs is below the average score, an attractive quality.
The sterol regulatory element-binding protein profile of analog 8 as studied in other research
shows promise that it may provide a superior side-effect consideration [69]. Given this
consideration, as well as its attractive placement as the third lowest DS in the study (DS =
0.12), we decide to include both species as recommendations for further study.
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Utilizing this expression profiling, analogs 3, 5, 8, 10 and 11 hold the most promise for
future work, as they have the lowest divergence scores and represent a diverse selection from
each of the analog archetype groupings. Studying RXR homodimerization and gene
expression in cultured CTCL cells is a quick and effective method to screen for the most
promising analogs; however, the next steps must include moving into an animal disease
model. There is promising work on a new mouse model of CTCL as well as excellent
information about rexinoid treatment of lung cancer and future steps must include
identifying in vivo side effect and lipid profiles of candidates, correlating these to the gene
expression profiles, and then judiciously treating model organisms of disease to determine
whole animal efficacy, with an eye towards clinical trials [70,71].
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New rexinoid synthesis should take into account the physical characteristics of the
molecules as they map out in Fig 6. Analogs which tend to have physical characteristics that
would group them tightly in group 1 are likely to produce more significantly different
expression profiles from bexarotene than are analogs that fit into groups 2 or 3.
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Refer to Web version on PubMed Central for supplementary material.
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•

CTCL cells reveal differential gene expression when treated with chemically
distinct rexinoids.

•

Rexinoids can be partitioned into discrete classes employing gene expression
profiles.

•

Minor variations in rexinoid structure lead to unique gene expression
signatures.

•

Divergence Scoring using expression profiles can lead to valuable structural
and decision making insights in rexinoid design.

•

Five of the twelve studied bexarotene analogs show promise for further
analysis/drug development.
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Bexarotene analog structures. Twelve bexarotene analogs were used to explore differential
gene expression in an in-vitro cutaneous T-cell lymphoma cell model. Microarray analysis
was employed to determine which among them show promise for further investigation and if
any trends emerge in their ability to regulate gene expression.
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Heat map of study genes. Heat map analysis of expression of genes from study gene list.
Gene expression was compared between analogs using 102 the genes outlined in the
Appendix.
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Figure 3.

Author Manuscript

Comparison and grouping of rexinoids via gene expression analysis. Figure 3a. Group 1
analogs versus bexarotene. Group 1 analogs contain those compounds which expressed the
most substantial changes from bexarotene. Members of this group have at least 4 study
genes with greater than |1.8| fold changes from bexarotene the number of study genes which
sort into one of 3 tranches representing increasing magnitudes of fold-changes from
bexarotene. Green bars represent the number of genes with a greater than 1.2 but less than
1.8 fold change (absolute) as compared to bexarotene. Yellow bars represent the number of
genes with a greater than 1.8 but less than 2.4 fold change (absolute) as compared to
bexarotene. Red bars represent the number of genes with a greater than 2.4 fold change
(absolute) as compared to bexarotene. Figure 3b. Group 2 analogs versus bexarotene. Group
2 analogs contain those compounds which expressed intermediate changes compared from
bexarotene as compared to groups 1 or 3. Members of this group have either least one study
genes with a greater than |1.8| fold change from bexarotene, or five or more total changes
from bexarotene of a magnitude greater than |1.2| fold. Green bars represent the number of
genes with a greater than 1.2 but less than 1.8 fold change (absolute) as compared to
bexarotene. Yellow bars represent the number of genes with a greater than 1.8 but less than
2.4 fold change (absolute) as compared to bexarotene. Red bars represent the number of
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genes with a greater than 2.4 fold change (absolute) as compared to bexarotene. Figure 3c.
Group 3 analogs versus bexarotene. Group 3 analogs contain those compounds which
expressed the fewest substantial changes from bexarotene. Members of this group have four
or fewer |1.8| magnitude fold change differences from bexarotene. Green bars represent the
number of genes with a greater than 1.2 but less than 1.8 fold change (absolute) as compared
to bexarotene.
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Figure 4.

Divergence scores by group. Divergence scoring (DS) first aggregates then averages
undesirable expression behavior from each analog across a subset of genes with well
understood activity. This allows for a relative metric for comparing the potential of each
analog to the others on the basis of their anti-oncogenic potential. Lower DS indicates a
more desirable expression profile on average, higher DS indicates a less desirable expression
profile on average. Group 1 analogs are in blue, group 2 analogs are in purple, and group 3
analogs are in green.
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Heat map of divergence score genes. Heat map analysis of expression of genes used to
calculate divergence score. Whiter hues indicate expression levels closer to parent molecule.
Bluer hues indicate expression that differs more drastically from parent molecule.
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Principal Component Analysis. Unit variance scaling is applied to rows; SVD with
imputation is used to calculate principal components. X and Y axis show principal
component 1 and principal component 2 that explain 52.1% and 34.7% of the total variance,
respectively. Prediction ellipses are such that with probability 0.95, a new observation from
the same group will fall inside the ellipse. N = 13 data points.
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Figure 7.
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Gene clustering based on RXR binding motifs. Genes were clustered (Euclidian, complete)
based on the presence (1, red or orange) or absence (0, green) of 9 known RXR binding
motifs. Unit variance scaling has been applied to each row, resulting in a scale of 0–3.
Analysis yielded 11 groups. Clusters 1–9 are shown. Cluster 10 (not shown) contains genes
that have no obvious RXR binding motif while cluster 11 (not shown) contains genes
containing all 9 motifs. N = 92 study genes that were successfully mapped to REFSEQ ID
numbers.
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Figure 8.

Bexarotene and analogs 3 and 12 in binding pocket. Pictured is the docking of analog 3 and
12 alongside their parent molecule in pocket. The binding pocket is viewed with helices 2, 4,
and 6 as reference points. Small chemical changes to the ligands of interest can produce
large differences to both their orientation in three-dimensional space as well as the way in
which they dock in the pocket.
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Figure 9.

Bexarotene and analogs 5 and 11 in binding pocket. Pictured is the docking of bexarotene
and analogs 5 and 11 in pocket. The binding pocket is viewed with helices 2, 4, and 6 as
reference points.
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Chemical compound analysis.
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Compound

cLogP1

cLogS2

tPSA3

MW4

Bexarotene

4.8

−6.4

37.3

348.49

1

3.9

−6.8

83.1

393.481

2

4.9

−6.7

37.3

366.48

3

5.0

−7.0

37.3

384.47

4

5.2

−6.5

57.5

364.49

5

5.9

−7.2

37.3

362.51

6

4.5

−6.2

37.3

346.47

7

3.9

−5.6

50.2

349.47

8

3.1

−4.7

63.1

350.46

9

4.7

−4.97

50.2

363.50

10

4.0

−4.0

63.1

364.49

11

4.9

−6.3

57.5

362.47

12

4.6

−6.5

37.3

364.46

Compounds were analyzed using DataWarrior for physical characteristics.

1

P is [conc]octanol/[conc]water.

2

S is water solubility [mols/Liter] at pH = 7.5 and 25 °C.

3

tPSA is topological polar surface area.

4

MW is molecular weight.
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RXR binding motifs in presumptive promoter regions.
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Matrix ID

Motif Name

# Genes

MA0065.1

PPARγ::RXRα

42

MA0065.2

PPARγ::RXRα_v2

38

MA0074.1

RXRα::VDR

45

MA0115.1

NR1H2::RXRα

37

MA0159.1

RARα::RXRα

37

MA0494.1

NR1H3::RXRα

30

MA0512.2

RXRα

31

MA0855.1

RXRβ

30

Consensus Sequence
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Matrix ID

Motif Name

# Genes

MA0856.1

RXRγ

33

Consensus Sequence
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0.99
0.80
0.85
1.00
0.00
0.03
0.99
0.42
0.86
0.17

Cluster 2

Cluster 3

Cluster 4

Cluster 5

Cluster 6

Cluster 7

Cluster 8

Cluster 9

Cluster 10

Cluster 11

0.01

0.99

0.91

0.99

0.82

0.09

0.00

0.01

0.36

0.13

0.87

0.02

0.11

0.79

0.94

0.86

0.86

0.11

0.97

0.08

RARα:RXRα

0.00

1.00

0.88

0.12

0.95

0.99

1.00

0.86

0.14

0.00

0.01

0.00

0.95

0.94

0.03

0.03

0.96

0.86

0.78

0.48

0.10

0.01

PPARγ::RXRα_v

0.00

1.00

0.91

0.50

0.91

1.00

1.00

0.06

0.15

0.11

0.03

NR1H2::RXRα

Results of Pscan-calculated z-tests are shown for each cluster. Motifs that were significantly enriched (p<0.05) are highlighted.

1

0.02

0.041

Cluster 1
0.89

RXRα::VDR

PPARγ::RXRα

Author Manuscript

NR1H3::RXRα

Author Manuscript

Significantly enriched RXR motifs in gene clusters.

0.00

1.00

0.97

0.85

0.99

1.00

1.00

0.91

0.00

0.01

0.00

RXRγ

0.00

1.00

0.97

0.73

0.99

1.00

1.00

0.91

0.01

0.00

0.01

RXR β

0.00

0.74

0.69

0.56

0.54

0.92

0.98

0.42

0.00

0.01

0.00

RXRα
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1.00

0.59

0.70

0.02

0.62

0.48

0.19

0.37

0.88

0.09

Cluster 2

Cluster 3

Cluster 4

Cluster 5

Cluster 6

Cluster 7

Cluster 8

Cluster 9

Cluster 10

Cluster 11

0.00

0.18

0.59

0.28

0.55

0.21

0.92

0.83

0.23

0.01

0.63

0.75

0.51

0.51

0.13

0.27

0.95

0.27

0.54

0.43

Analog 3

0.40

0.63

0.45

0.64

0.00

0.11

0.03

0.98

0.12

0.62

0.01

0.32

0.09

0.33

0.50

0.14

0.04

0.07

0.90

0.02

0.87

0.00

Analog 5

0.52

0.54

0.43

0.45

0.82

0.51

0.41

0.05

0.66

0.33

0.88

Analog 6

0.57

0.86

0.15

0.76

0.52

0.73

0.61

0.49

0.58

0.31

0.74

Analog 7

0.63

0.29

0.41

0.37

0.62

0.25

0.43

0.89

0.75

0.04

0.29

Analog 8

0.08

0.64

0.40

0.52

0.97

0.07

0.95

0.21

0.67

0.63

0.62

Analog 9

0.40

0.07

0.57

0.49

0.93

0.18

0.64

0.28

0.80

0.34

0.80

Analog 10

Gene clusters which responded significantly differently (p<0.5) following rexinoid treatment compared to remaining study genes are highlighted.

1

0.25

0.021

Cluster 1
0.71

Analog2

Analog 4

Author Manuscript

Analog 1

Author Manuscript

Cluster-specific response to Analogs.

0.20

0.26

0.19

0.51

0.83

0.85

0.47

0.67

0.45

0.40

0.73

Analog 11

0.40

0.25

0.06

0.46

0.25

0.20

0.30

0.01

0.84

0.47

0.80

Analog 12
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4 R = OH
5 R = CH3

4 R = OH
5 R = CH3

3

2

1

Analog

RXRα::VDR

1
5

−0.10
+0.02

+0.58
+0.38

NR1H3::RXRα
PPARγ::RXRα_v2

RXRγ
RXRβ
RXRα

1
7

1
3

−0.10
−0.10

12

11

10

9

11

+0.17

RXRα::VDR
PPARγ::RXRα
PPARγ::RXRα_v2
NR1H2::RXRα
RXRα
RXRγ
RXRβ

7

8

+0.38

+0.71
+0.58

11

RXRα::VDR

1
5

Expression relative to
Bexarotene

RXRα::VDR
PPARγ::RXRα
PPARγ::RXRα_v2
NR1H2::RXRα
RXRα
RXRγ
RXRβ

Shared Motifs

Clusters

Analog

Author Manuscript

Clusters and motifs associated with significant changes in gene expression for each analog.

4

-

-

-

2

-

Clusters

RXRα::VDR

-

-

-

PPARγ::RXRα
RXRγ
RXRβ
RXRα

-

Shared Motifs

+0.43

-

-

-

+0.21

-

Expression relative to
Bexarotene
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6

NR1H3::RXRα

RXRα::VDR

1
6

4

Author Manuscript
Shared Motifs

−0.98

+0.58
−0.83

Expression relative to
Bexarotene
Analog

Author Manuscript

Clusters

Clusters

Shared Motifs

Expression relative to
Bexarotene
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